Dynavax Technologies (NASDAQ: DVAX)
Dynavax Technologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Dynavax Technologies Company Info
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
News & Analysis
Why Dynavax Stock Popped by Over 5% Today
One pundit believes the share price could more than double.
Why Dynavax Stock Was Crushing It on Friday
The company delivered resounding beats on both the top and bottom lines in the second quarter.
Why Dynavax Crushed the Market on Thursday
Its partner's coronavirus vaccine comes one important step closer to approval in Europe.
Why Dynavax Stock Blasted 16% Higher Today
One of its vaccine partners had some encouraging regulatory news to report.
Why Dynavax Stock Won on a Losing Monday for the Market
The company earns an Emergency Use Authorization from a well-off Middle Eastern country.
Why Dynavax Stock Was Winning This Week
Several coronavirus vaccines using the company's adjuvant are advancing up the regulatory ladder.
Why Dynavax Stock Dipped on Tuesday
Investors weren't inspired by the bitoech's mixed Q4.
Why Dynavax Stock Zoomed Higher Today
One analyst gets notably more bullish on the biotech's shares.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.